The company filed for the draft red herring prospectus with Sebi. It plans to raise Rs 600 crore by selling 24 million equity shares.
Out of the total shares on offer, 50 per cent have been reserved for QIBs, 15 per cent for high net worth individuals and 35 per cent for retail investors.
In January this year Biocon concluded sale of 10 per cent stake in Syngene for Rs 380 crore to IVF Trustee Company Private Ltd. The deal had put the entire valuation of Syngene International Ltd at Rs 3,800 crore.
The plan has remained unexecuted since 2012 due to uncertainties in global and domestic economic environment.
(With PTI inputs)
Get Breaking news, live coverage, and Latest News from India and around the world on NDTV.com. Catch all the Live TV action on NDTV 24x7 and NDTV India. Like us on Facebook or follow us on Twitter and Instagram for latest news and live news updates.